PRINCIPEN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Principen, and when can generic versions of Principen launch?
Principen is a drug marketed by Apothecon and Bristol Myers Squibb and is included in nine NDAs.
The generic ingredient in PRINCIPEN is ampicillin/ampicillin trihydrate; probenecid. Additional details are available on the ampicillin/ampicillin trihydrate; probenecid profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PRINCIPEN?
- What are the global sales for PRINCIPEN?
- What is Average Wholesale Price for PRINCIPEN?
Summary for PRINCIPEN
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 9 |
| Raw Ingredient (Bulk) Api Vendors: | 78 |
| Patent Applications: | 4,228 |
| DailyMed Link: | PRINCIPEN at DailyMed |
US Patents and Regulatory Information for PRINCIPEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apothecon | PRINCIPEN | ampicillin/ampicillin trihydrate | CAPSULE;ORAL | 062888-001 | Mar 4, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Apothecon | PRINCIPEN | ampicillin/ampicillin trihydrate | FOR SUSPENSION;ORAL | 061394-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | PRINCIPEN | ampicillin/ampicillin trihydrate | CAPSULE;ORAL | 061392-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Apothecon | PRINCIPEN '250' | ampicillin/ampicillin trihydrate | FOR SUSPENSION;ORAL | 060127-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
